Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600X Vemurafenib cholangiocarcinoma sensitive detail...
FGFR2 fusion Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 mutant Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - ZMYM4 FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 E565A FGFR2 K659M Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - OPTN FGFR2 N549H FGFR2 V564F FGFR2 E565A FGFR2 L617V FGFR2 K641R Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - BICC1 FGFR2 V564F Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 fusion FGFR2 V564F Infigratinib cholangiocarcinoma predicted - resistant detail...
IDH1 mutant Ivosidenib cholangiocarcinoma sensitive detail...
FGFR2 fusion Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange FGFR2 amp Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 - DDX21 Debio 1347 cholangiocarcinoma sensitive detail...
FGFR2 - KIAA1217 Debio 1347 cholangiocarcinoma predicted - sensitive detail...
FGFR2 - ROCK1 Debio 1347 cholangiocarcinoma predicted - sensitive detail...
FGFR2 mutant Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR3 mutant Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - PPHLN1 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Infigratinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Infigratinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Infigratinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 AZD4547 cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Erdafitinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Futibatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A AZD4547 cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Erdafitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Futibatinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 Dovitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Dovitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M AZD4547 cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Erdafitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Futibatinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - TTC28 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 fusion Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 - BICC1 Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 - CLIP1 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CLIP1 FGFR2 N549H Pemigatinib cholangiocarcinoma predicted - resistant detail...
BRAF V600E Vemurafenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132C Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132S Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132L Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132G Ivosidenib cholangiocarcinoma predicted - sensitive detail...
FGFR3 amp Infigratinib cholangiocarcinoma no benefit detail...
FGFR2 amp Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - BICC1 Sorafenib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - BICC1 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - BICC1 AZD4547 cholangiocarcinoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion ICP-192 cholangiocarcinoma predicted - sensitive detail...
FGFR2 - KIAA1217 FGFR2 K659M Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - AHCYL1 FGFR2 L617V Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 rearrange Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - NRBF2 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - NRBF2 FGFR2 N549K Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - KIAA1217 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CCDC170 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CCDC170 FGFR2 N549K FGFR2 K641R Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - AHCYL1 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - WDHD1 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - PAWR Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - ATAD2 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - ATAD2 FGFR2 N549H Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - TRIM8 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - TRIM8 FGFR2 E565A FGFR2 L617V FGFR2 K659M Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - DDX21 FGFR2 K659M FGFR2 Y779C Debio 1347 cholangiocarcinoma predicted - resistant detail...
FGFR2 - KIAA1217 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - KIAA1217 FGFR2 L550F Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - KIAA1217 FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 V564I FGFR2 V564L FGFR2 E565A FGFR2 L617F FGFR2 L617V FGFR2 K659M FGFR2 Q746L Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - NRAP Infigratinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - NRAP FGFR2 N549K FGFR2 V564L Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 M537I FGFR2 V564L FGFR2 amp Infigratinib cholangiocarcinoma predicted - resistant detail...
IDH1 R132H Ivosidenib cholangiocarcinoma sensitive detail...
FGFR2 - WAC Infigratinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - WAC FGFR2 M537I FGFR2 M538L FGFR2 N549H FGFR2 N549K FGFR2 N549T FGFR2 L550F FGFR2 V564F FGFR2 V564I FGFR2 E565A FGFR2 D650Y FGFR2 N652S FGFR2 K659Q Infigratinib cholangiocarcinoma predicted - resistant detail...
IDH1 R132S Ceralasertib + Olaparib cholangiocarcinoma sensitive detail...
FGFR2 C382R Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CCDC6 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CCDC6 FGFR2 N549D FGFR2 N549K FGFR2 V564I Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - USP33 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting USA 0
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA | FRA | ESP | DEU 2
NCT01825603 Phase I ADH-1 + Cisplatin + Gemcitabine ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Completed USA 0
NCT01888302 Phase I Cisplatin + Gemcitabine + Sirolimus Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery Completed USA 0
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 7
NCT02053376 Phase II Regorafenib A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Completed USA 0
NCT02128282 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Silmitasertib Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Completed USA 2
NCT02150967 Phase II Infigratinib A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Active, not recruiting USA | ITA | ESP | DEU | BEL 6
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN 1
NCT02232633 Phase II Amcasertib A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer Completed CAN 0
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed USA | ITA 3
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Completed USA 1
NCT02452970 Phase II RRx-001 Cisplatin + Gemcitabine RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) Terminated USA 0
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated USA 1
NCT02508467 Phase I Fisogatinib A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma Active, not recruiting USA | ITA | FRA | ESP | DEU 7
NCT02520141 Phase II Ramucirumab Ramucirumab for Advanced Pre-treated Biliary Cancers Active, not recruiting USA 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | ITA | FRA | ESP | DEU | CAN 14
NCT02632305 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) Unknown status CAN 0
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02711553 Phase II Ramucirumab Merestinib Cisplatin + Gemcitabine A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting USA | FRA | ESP | DEU | BEL | AUT 13
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | FRA | ESP | BEL 2
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting USA 1
NCT02856568 Phase I Cisplatin + Gemcitabine + Ricolinostat Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn USA 0
NCT02924376 Phase II Pemigatinib Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy Completed USA | ITA | FRA | ESP | DEU | BEL 6
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Active, not recruiting USA 0
NCT02982720 Phase II Peginterferon alfa-2b + Pembrolizumab Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron Terminated USA 0
NCT02989857 Phase III Ivosidenib Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Completed USA | ITA | FRA | ESP 2
NCT03093870 Phase II Capecitabine + Varlitinib Capecitabine Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Completed USA | ESP 9
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Active, not recruiting USA 0
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | ITA | FRA | ESP | CAN | BEL 6
NCT03132792 Phase I AFPc332T AFPc332T in Advanced HCC Recruiting USA | FRA | ESP 1
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA | BEL 0
NCT03201458 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Active, not recruiting USA 0
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Recruiting USA 0
NCT03230318 Phase II Derazantinib Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 4
NCT03250273 Phase II Entinostat + Nivolumab A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Completed USA 0
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Active, not recruiting USA 0
NCT03267940 Phase I Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Gemcitabine + PEGPH20 Cisplatin + Gemcitabine + PEGPH20 Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Terminated USA 2
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT03339843 Phase II Abemaciclib Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) Active, not recruiting FRA | BEL 0
NCT03368963 Phase Ib/II MM-398 + Trifluridine-tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting USA 0
NCT03377179 Phase II ABC294640 A Study of ABC294640 in the Treatment of Patients With Advanced Cholangiocarcinoma Active, not recruiting USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting USA | FRA | ESP | DEU 3
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting USA 0
NCT03656536 Phase III Pemigatinib Cisplatin + Gemcitabine A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 11
NCT03704480 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) Recruiting FRA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Recruiting USA | FRA | ESP 3
NCT03773302 Phase III Cisplatin + Gemcitabine Infigratinib Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 8
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 11
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting USA | FRA 0
NCT03878095 Phase II Ceralasertib + Olaparib Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors Recruiting USA 0
NCT03943004 Phase I DFP-14927 Trial of DFP-14927 in Advanced Solid Tumors Recruiting USA 0
NCT04003636 Phase III Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 17
NCT04003896 Phase II Abemaciclib A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy Recruiting USA 0
NCT04034238 Phase I LMB-100 + Tofacitinib Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Active, not recruiting USA 0
NCT04057365 Phase II DKN-01 + Nivolumab A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Recruiting USA 0
NCT04068194 Phase Ib/II Avelumab Avelumab + Peposertib Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Recruiting USA 0
NCT04088188 Phase I Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Recruiting USA 0
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Recruiting USA | ESP | DEU 2
NCT04175912 Phase II Carboplatin + MLN4924 + Paclitaxel MLN4924 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Suspended USA 0
NCT04233567 Phase II Infigratinib Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Recruiting USA 0
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Recruiting USA 0
NCT04306367 Phase II Olaparib + Pembrolizumab Study of Pembrolizumab and Olaparib in Bile Duct Cancer Recruiting USA 0
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04421820 Phase I BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Recruiting CAN 0
NCT04430738 Phase Ib/II Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Recruiting USA 0
NCT04507503 Expanded access Futibatinib Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Available USA 0
NCT04521686 Phase I LY3410738 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Recruiting USA | FRA | ESP 6
NCT04565275 Phase Ib/II ICP-192 A Study of ICP-192 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04641871 Phase I Sym021 + Sym023 Sym021 + Sym022 Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies Recruiting USA | FRA | ESP | CAN 0
NCT04645160 Phase Ib/II Tivozanib Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma Recruiting USA 0
NCT04648319 Phase II Nivolumab A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma Terminated BEL 2
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Recruiting USA | CAN 0
NCT04676633 Phase I Cotsiranib Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy Recruiting USA 0
NCT04677504 Phase II Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer Active, not recruiting USA | ITA | ESP 10
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Active, not recruiting USA | ITA | FRA | BEL 4
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04781192 Phase Ib/II Durvalumab + Regorafenib The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Recruiting USA 0
NCT04914286 Phase Ib/II GFH018 + Toripalimab A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Recruiting 1
NCT04919642 Phase II TT-00420 Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma Recruiting USA 0
NCT04973163 Phase I BI 1823911 + Midazolam BI 1701963 + BI 1823911 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Recruiting USA | ESP | BEL 1
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Recruiting USA 0
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA | ITA | FRA | ESP | DEU | CAN 9
NCT05123482 Phase Ib/II AZD8205 First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Recruiting USA 4
NCT05176665 Phase Ib/II EMB-01 EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers Recruiting USA 1
NCT05211323 Phase II Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer Recruiting USA 0